A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Inclusion Criteria:

* Male and female aged 18-75 years old. The subjects must have informed consent to the study, and signed the written informed consent voluntarily.
* Diagnosis as non resectable local advanced or metastatic pancreatic cancer by histology or cytology.
* Measurable disease as defined by RECIST 1.1.
* Without systemic treatment for pancreatic cancer.
* ECOG physical strength score 0-2
* Estimated survival time \>=3 months.
* The adequate bone marrow fuction and coagulation function

Exclusion Criteria:

* Known allergy or hypersensitivity to any components of the investigational drug product.
* Previous treatment with highly selective inhibitors targeting Colony Stimulating Factor 1 (CSF-1)/Colony Stimulating Factor 1 Receptor (CSF-1R).
* With Breast Cancer Gene 1/2 (BRCA1/2) gene mutation.
* With a history of other malignancies within 5 years.
* During the trial, other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except for local symptomatic radiotherapy) or traditional Chinese medicine must be used for anti-tumor treatment.
* With conditions that significantly affected the absorption of oral drug.
* Surgical treatment is required within 4 weeks before the first administration, or unhealed, infected, or dehiscence of previous surgical wounds.
* During the 2 weeks prior to the first administration of this study, the patient was receiving chronic systemic steroid treatment or any other form of immunosuppressive treatment.
* Concomitant use of strong inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4) within 14 days prior to randomization.
* Previous peripheral neuropathy \> grade 1 (Common Terminology Criteria for Adverse Events, version 5.0).
* Diagnosed with immune deficiency or interstitial lung disease.
* The patients were vaccinated within 4 weeks before the first treatment.
* Participated in any drug clinical trial within 4 weeks before the first treatment.
* Active central nervous system (CNS) metastases.
* Impaired cardiac function or clinically significant cardiac disease.
* Known active liver or biliary disease, or other diseases that may lead to abnormal liver function test results during the study.
* Known active infections from certain viruses, bacteria or parasites.
* Patients with refractory/uncontrolled ascites or pleural effusion.
* Pregnant or lactating women.
* Any other clinically significant comorbidities, which in the judgment of the Investigator, should not be included.